C07D271/06

PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES
20170362192 · 2017-12-21 ·

The present invention provides processes for the preparation of ataluren. Intermediates for preparing ataluren are also provided.

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
20220380299 · 2022-12-01 ·

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
20220380299 · 2022-12-01 ·

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof

The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development. ##STR00001##

Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof

The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development. ##STR00001##

Crystalline forms of 3-substituted 1,2,4-oxadiazole

The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.

Crystalline forms of 3-substituted 1,2,4-oxadiazole

The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.

4-DIFLUOROMETHYL BENZOYL AMIDES WITH HERBICIDAL ACTION

Benzoylamides of the general formula (I) are described as herbicides.

##STR00001##

In this formula (I), X, R and R.sup.a represent radicals such as alkyl, cycloalkyl and halogen. Q represents a five-membered heterocycle.

4-DIFLUOROMETHYL BENZOYL AMIDES WITH HERBICIDAL ACTION

Benzoylamides of the general formula (I) are described as herbicides.

##STR00001##

In this formula (I), X, R and R.sup.a represent radicals such as alkyl, cycloalkyl and halogen. Q represents a five-membered heterocycle.

CRYSTALLINE FORM OF OZANIMOD HYDROCHLORIDE
20230183194 · 2023-06-15 ·

The presented invention relates to crystalline form, Form A of Ozanimod hydrochloride, processes for preparation thereof and pharmaceutical compositions comprising the Ozanimod hydrochloride Form A.